What I am working with: ERP · SGN · New Zealand.
I suspect the honest answer is that it depends, in which case I would like to know on what.
Assume I can obtain either option without difficulty, so availability is not the deciding factor.
What is the actual trade-off, and does it matter at the scale I am working at?
On the detail: ratings on this site are ours alone and are deliberately not reconciled with anyone else's.
Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.
To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.
Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Compare content, not purity. Purity clusters and content does not.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the axis. A supplier that is best on paperwork and a supplier that is best on price are both correct answers to different questions.
Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.
The relevant detail is that publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.
The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.
Price per milligram of measured peptide, not per milligram of label claim.
This is the question where methodology matters more than the conclusion.
Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.
Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.
Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.
Name the laboratory and the dates or the comparison cannot be reproduced.
A single member running three suppliers on one method is worth more than thirty members running one supplier each.
Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.
The caveat is that a comparison is a snapshot of the lots compared, and lots change.
One laboratory, one method, one submission. Otherwise it is not a comparison.
Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.
Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.
No supplier on this site pays for its position, and the storefront links are marked nofollow and sponsored.
Use a fixed documentation checklist rather than an impression.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.